Department of Radiation Oncology, Vanderbilt University, Nashville, Tennessee, United States of America.
PLoS One. 2012;7(9):e45402. doi: 10.1371/journal.pone.0045402. Epub 2012 Sep 17.
Malignant gliomas represent one group of tumors that poorly respond to ionizing radiation (IR) alone or combined with chemotherapeutic agents because of the intrinsic or acquired resistance. In this study, TIP-1 was identified as one novel protein that confers resistance of glioma cells to IR.
METHODOLOGY/PRINCIPAL FINDINGS: Meta-analysis indicated that high TIP-1 expression levels correlate with the poor prognosis of human malignant gliomas after radiotherapy. Studies with established human glioma cell lines demonstrated that TIP-1 depletion with specific shRNAs sensitized the cells to IR, whereas an ectopic expression of TIP-1 protected the glioma cells from the IR-induced DNA damage and cell death. Biochemical studies indicated that TIP-1 protein promoted p53 ubiquitination and resulted in a reduced p53 protein level. Furthermore, p53 and its ubiquitination are required for the TIP-1 regulated cellular response to IR. A yeast two-hybrid screening identified that TIP-1, through its single PDZ domain, binds to the carboxyl terminus of LZAP that has been studied as one tumor suppressor functioning through ARF binding and p53 activation. It was revealed that the presence of TIP-1 enhances the protein association between LZAP and ARF and modulates the functionality of ARF/HDM2 toward multi-ubiquitination of p53, while depleting TIP-1 rescued p53 from polyubiquitination and degradation in the irradiated glioma cells. Studies with a mouse xenograft model indicated that depleting TIP-1 within D54 cells improved the tumor growth control with IR.
CONCLUSIONS/SIGNIFICANCE: This study provided the first evidence showing that TIP-1 modulates p53 protein stability and is involved in the radioresistance of malignant gliomas, suggesting that antagonizing TIP-1 might be one novel approach to sensitize malignant gliomas to radiotherapy.
恶性神经胶质瘤是对电离辐射(IR)单独或联合化疗药物反应不良的肿瘤之一,这是由于内在或获得性耐药。在这项研究中,TIP-1 被鉴定为一种赋予神经胶质瘤细胞对 IR 抗性的新型蛋白。
方法/主要发现:荟萃分析表明,TIP-1 高表达水平与接受放疗后人类恶性神经胶质瘤的不良预后相关。用已建立的人类神经胶质瘤细胞系进行的研究表明,用特异性 shRNA 耗尽 TIP-1 可使细胞对 IR 敏感,而 TIP-1 的异位表达可保护神经胶质瘤细胞免受 IR 诱导的 DNA 损伤和细胞死亡。生化研究表明,TIP-1 蛋白促进 p53 泛素化,导致 p53 蛋白水平降低。此外,p53 及其泛素化是 TIP-1 调节细胞对 IR 反应所必需的。酵母双杂交筛选表明,TIP-1 通过其单个 PDZ 结构域与 LZAP 的羧基末端结合,LZAP 已被研究为一种通过 ARF 结合和 p53 激活发挥作用的肿瘤抑制因子。结果表明,TIP-1 的存在增强了 LZAP 和 ARF 之间的蛋白质相互作用,并调节了 ARF/HDM2 对 p53 多泛素化的功能,而耗尽 TIP-1 可使照射后的神经胶质瘤细胞中的 p53 免受多泛素化和降解。用小鼠异种移植模型进行的研究表明,在 D54 细胞中耗尽 TIP-1 可改善 IR 对肿瘤生长的控制。
结论/意义:本研究首次证明 TIP-1 调节 p53 蛋白稳定性,并参与恶性神经胶质瘤的放射抵抗,提示拮抗 TIP-1 可能是一种使恶性神经胶质瘤对放疗敏感的新方法。